Alpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025

Reuters

Nov 14, 2025

<a href="https://laohu8.com/S/ACOG">Alpha Cognition</a> Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025

Alpha Cognition Inc. (NASDAQ: ACOG) reported business updates for the third quarter of 2025, highlighting continued momentum in the commercialization of ZUNVEYL®. Revenue for the quarter reached $2.8 million, consisting of $2.3 million in ZUNVEYL net product sales and $0.5 million in licensing revenue, reflecting strong sequential growth. Pharmacy orders grew by 102% compared to the previous quarter, with ZUNVEYL now reaching more than 600 nursing homes and the prescriber base exceeding 500 clinicians. The company reported pro forma cash of approximately $73.2 million following an equity raise in October, which is expected to provide about two years of operational runway. The company also retains access to a $75 million ATM facility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 274515) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583024765"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583024765\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583024765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583024765","market":"fut","top_or_hot":-1,"title":"Alpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACOG\">Alpha Cognition</a> Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACOGD\">Alpha Cognition Inc.</a> (NASDAQ: ACOG) reported business updates for the third quarter of 2025, highlighting continued momentum in the commercialization of ZUNVEYL®. Revenue for the quarter reached $2.8 million, consisting of $2.3 million in ZUNVEYL net product sales and $0.5 million in licensing revenue, reflecting strong sequential growth. Pharmacy orders grew by 102% compared to the previous quarter, with ZUNVEYL now reaching more than 600 nursing homes and the prescriber base exceeding 500 clinicians. The company reported pro forma cash of approximately $73.2 million following an equity raise in October, which is expected to provide about two years of operational runway. The company also retains access to a $75 million ATM facility.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ACOGF\">Alpha Cognition Inc.</a> published the original content used to generate this news brief via Newsfile (Ref. ID: 274515) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACOG\">Alpha Cognition</a> Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACOGD\">Alpha Cognition Inc.</a> (NASDAQ: ACOG) reported business updates for the third quarter of 2025, highlighting continued momentum in the commercialization of ZUNVEYL®. Revenue for the quarter reached $2.8 million, consisting of $2.3 million in ZUNVEYL net product sales and $0.5 million in licensing revenue, reflecting strong sequential growth. Pharmacy orders grew by 102% compared to the previous quarter, with ZUNVEYL now reaching more than 600 nursing homes and the prescriber base exceeding 500 clinicians. The company reported pro forma cash of approximately $73.2 million following an equity raise in October, which is expected to provide about two years of operational runway. The company also retains access to a $75 million ATM facility.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ACOGF\">Alpha Cognition Inc.</a> published the original content used to generate this news brief via Newsfile (Ref. ID: 274515) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACOG","symbol_name":"ALPHA COGNITION INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLWD829:1","article_id":"2583024765","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583024765","pubTimestamp":1763131638,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alpha Cognition Inc.  reported business updates for the third quarter of 2025, highlighting continued momentum in the commercialization of ZUNVEYL. Revenue for the quarter reached $2.8 million, consisting of $2.3 million in ZUNVEYL net product sales and $0.5 million in licensing revenue, reflecting strong sequential growth. Pharmacy orders grew by 102% compared to the previous quarter, with ZUNVEYL now reaching more than 600 nursing homes and the prescriber base exceeding 500 clinicians. The company reported pro forma cash of approximately $73.2 million following an equity raise in October, which is expected to provide about two years of operational runway. The company also retains access to a $75 million ATM facility.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACOG":"ALPHA COGNITION INC","BK4139":"生物科技"},"translate_title":"Alpha Cognition报告2025年第三季度收入为280万美元，并扩大ZUNVEYL的采用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACOG":0.9},"content_text":"Alpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025\n    \n\nAlpha Cognition Inc. (NASDAQ: ACOG) reported business updates for the third quarter of 2025, highlighting continued momentum in the commercialization of ZUNVEYL®. Revenue for the quarter reached $2.8 million, consisting of $2.3 million in ZUNVEYL net product sales and $0.5 million in licensing revenue, reflecting strong sequential growth. Pharmacy orders grew by 102% compared to the previous quarter, with ZUNVEYL now reaching more than 600 nursing homes and the prescriber base exceeding 500 clinicians. The company reported pro forma cash of approximately $73.2 million following an equity raise in October, which is expected to provide about two years of operational runway. The company also retains access to a $75 million ATM facility.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 274515) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}